COVID-19 Vaccine Efficacy in Pediatric Solid Organ Transplant Recipients

Strategic Insights -

Pediatric solid organ transplant recipients are at a higher risk of developing severe COVID-19 complications due to their compromised immune systems. A new study conducted by researchers at Stanford University has investigated the effectiveness of the SARS-CoV-2 vaccine in this population. The study found that after three doses of the mRNA vaccine, the majority of pediatric solid organ transplant recipients demonstrated robust cell-mediated and humoral responses to the virus. The results suggest that three doses of the SARS-CoV-2 vaccine are effective in inducing a strong immune response in pediatric solid organ transplant recipients.

Key Takeaways:

  • The study included 33 pediatric solid organ transplant recipients aged 5-17 years who received 2-3 doses of the SARS-CoV-2 mRNA vaccine.
  • After the third dose (V3), 100% of the subjects had a positive IgG response, indicating a humoral response to the vaccine.
  • 94.1% of the subjects (16/17) had a positive IGRA response after V3, indicating a cell-mediated response to the vaccine.
  • RBD-ACE2 blocking antibody levels increased significantly from V2 to V3 (p = .007).
  • The study concluded that SARS-CoV-2 vaccination induces humoral and cell-mediated responses in the majority of pediatric solid organ transplant recipients, with improved quantitative humoral response after three doses.

Statistics:

  • 100% (19/19) of subjects had a positive IgG response after the third dose of the vaccine.
  • 94.1% (16/17) of subjects had a positive IGRA response after the third dose of the vaccine.
  • 33 pediatric solid organ transplant recipients were included in the study.
  • The study found a significant increase in RBD-ACE2 blocking antibody levels from V2 to V3 (p = .007).
  • 21 subjects were tested after the third dose of the vaccine.

Sources:

  • American Journal of Transplantation, 2022.
  • Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (www.wiley.com/; onlinelibrary.wiley.com/journal/10.1111/(ISSN)1600-6143)
  • NewsRx. New COVID-19 Study Findings Have Been Reported by Researchers at Stanford University (Pediatric Solid Organ Transplant Recipients Demonstrate Robust Cell-mediated and Humoral Responses To Three Doses of Mrna Sars-cov-2 Vaccine). Medical Letter on the CDC & FDA. October 30, 2022; p 288.